We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-3.41%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$800M
AUM Growth
-$94.7M
Cap. Flow
-$16.1M
Cap. Flow %
-2.01%
Top 10 Hldgs %
66.9%
Holding
36
New
3
Increased
1
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$44.4M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$43.2M
3
CBAY
Cymabay Therapeutics
CBAY
+$20M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.8M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$51.1M
2
NTRA icon
Natera
NTRA
+$33.6M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$25.8M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.2M
5
TVRD
Tvardi Therapeutics
TVRD
+$4.57M

Sector Composition

Rank Sector Weight
1 Healthcare 98.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
1
NewAmsterdam Pharma
NAMS
$3.34B
$110M 13.76%
8,300,000
– –
NUVL
2
DELISTED
Nuvalent
NUVL
$93.3M 11.66%
3,577,267
– –
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$79.3M 9.91%
3,081,307
-1,750,000
-36% -$51.1M
IRON icon
4
Disc Medicine
IRON
$3.01B
$42.2M 5.27%
+1,990,914
New +$44.4M
NTRA icon
5
Natera
NTRA
$45.9B
$38.9M 4.86%
700,197
-699,803
-50% -$33.6M
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$38.4M 4.8%
3,915,000
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.93B
$37M 4.63%
2,305,558
– –
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$35.6M 4.45%
346,547
– –
ARQT icon
9
Arcutis Biotherapeutics
ARQT
$3.26B
$33M 4.12%
3,000,000
– –
ACRS icon
10
Aclaris Therapeutics
ACRS
$867M
$27.5M 3.44%
+3,400,000
New +$43.2M
PHVS icon
11
Pharvaris
PHVS
$2.43B
$25.6M 3.2%
3,180,601
– –
SVRA icon
12
Savara
SVRA
$1.17B
$22.7M 2.83%
11,622,598
– –
CBAY
13
DELISTED
Cymabay Therapeutics
CBAY
$21.8M 2.72%
+2,500,000
New +$20M
CTIC
14
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$19.8M 2.47%
4,702,996
+925,688
+25% +$4.8M
EQRX
15
DELISTED
EQRx, Inc. Common Stock
EQRX
$19.4M 2.43%
10,003,573
– –
ANNX icon
16
Annexon
ANNX
$883M
$18.8M 2.35%
4,886,616
– –
NRIX icon
17
Nurix Therapeutics
NRIX
$2.69B
$16.2M 2.02%
1,822,883
– –
SLDB icon
18
Solid Biosciences
SLDB
$918M
$14.8M 1.85%
3,130,422
– –
TSVT
19
DELISTED
2seventy bio
TSVT
$14.4M 1.8%
1,408,901
– –
RPID icon
20
Rapid Micro Biosystems
RPID
$85.2M
$11M 1.38%
8,434,560
– –
TVRD
21
Tvardi Therapeutics
TVRD
$22M
$10.8M 1.35%
61,235
-13,655
-18% -$4.57M
XFOR icon
22
X4 Pharmaceuticals
XFOR
$421M
$10.6M 1.33%
406,750
– –
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$9.87M 1.23%
1,431,058
– –
XLO icon
24
Xilio Therapeutics
XLO
$60.5M
$8.89M 1.11%
200,387
– –
AVIR icon
25
Atea Pharmaceuticals
AVIR
$402M
$8.33M 1.04%
2,485,638
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q1 2023 Portfolio in Review

As of Q1 2023, Bain Capital Life Sciences Investors held 36 positions worth $800M, down 11% from $895M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Bain Capital Life Sciences Investors's Q1 2023 filing shows 3 new, 1 increased, 4 reduced and 2 closed positions. Its largest new stake was Disc Medicine: 1,990,914 shares worth $42.2M. The largest sale was SpringWorks Therapeutics, an estimated $51.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

  • Bain Capital Life Sciences Investors's largest Q1 2023 buy was Disc Medicine: 1,990,914 shares worth $42.2M.
  • Bain Capital Life Sciences Investors added most to CTI BioPharma Corp. (DE) Common Stock in Q1 2023, an estimated $4.8M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2023 reduction was SpringWorks Therapeutics, cutting an estimated $51.1M.
  • Bain Capital Life Sciences Investors fully exited Protagonist Therapeutics in Q1 2023, selling an estimated $25.8M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 67% of its $800M portfolio in Q1 2023.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 2 in Q1 2023.
  • Bain Capital Life Sciences Investors's portfolio value fell 11% quarter-over-quarter to $800M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2023, filed 15 May 2023.